Literature DB >> 21847359

Enhanced expression of EHMT2 is involved in the proliferation of cancer cells through negative regulation of SIAH1.

Hyun-Soo Cho1, John D Kelly, Shinya Hayami, Gouji Toyokawa, Masahi Takawa, Masanori Yoshimatsu, Tatsuhiko Tsunoda, Helen I Field, David E Neal, Bruce Aj Ponder, Yusuke Nakamura, Ryuji Hamamoto.   

Abstract

EHMT2 is a histone lysine methyltransferase localized in euchromatin regions and acting as a corepressor for specific transcription factors. Although the role of EHMT2 in transcriptional regulation has been well documented, the pathologic consequences of its dysfunction in human disease have not been well understood. Here, we describe important roles of EHMT2 in human carcinogenesis. Expression levels of EHMT2 are significantly elevated in human bladder carcinomas compared with nonneoplastic bladder tissues (P < .0001) in real-time polymerase chain reaction analysis. Complementary DNA microarray analysis also revealed its overexpression in various types of cancer. The reduction of EHMT2 expression by small interfering RNAs resulted in the suppression of the growth of cancer cells and possibly caused apoptotic cell death in cancer cells. Importantly, we show that EHMT2 can suppress transcription of the SIAH1 gene by binding to its promoter region (-293 to +51) and by methylating lysine 9 of histone H3. Furthermore, an EHMT2-specific inhibitor, BIX-01294, significantly suppressed the growth of cancer cells. Our results suggest that dysregulation of EHMT2 plays an important role in the growth regulation of cancer cells, and further functional studies may affirm the importance of EHMT2 as a promising therapeutic target for various types of cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21847359      PMCID: PMC3156658          DOI: 10.1593/neo.11512

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  40 in total

1.  The language of covalent histone modifications.

Authors:  B D Strahl; C D Allis
Journal:  Nature       Date:  2000-01-06       Impact factor: 49.962

Review 2.  Histone methylation in transcriptional control.

Authors:  Tony Kouzarides
Journal:  Curr Opin Genet Dev       Date:  2002-04       Impact factor: 5.578

3.  Uroplakin gene expression in normal human tissues and locally advanced bladder cancer.

Authors:  Jonathon Olsburgh; Patricia Harnden; Robert Weeks; Barbara Smith; Adrian Joyce; Geoffrey Hall; Richard Poulsom; Peter Selby; Jennifer Southgate
Journal:  J Pathol       Date:  2003-01       Impact factor: 7.996

4.  Alterations of gene expression during colorectal carcinogenesis revealed by cDNA microarrays after laser-capture microdissection of tumor tissues and normal epithelia.

Authors:  O Kitahara; Y Furukawa; T Tanaka; C Kihara; K Ono; R Yanagawa; M E Nita; T Takagi; Y Nakamura; T Tsunoda
Journal:  Cancer Res       Date:  2001-05-01       Impact factor: 12.701

5.  Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain.

Authors:  A J Bannister; P Zegerman; J F Partridge; E A Miska; J O Thomas; R C Allshire; T Kouzarides
Journal:  Nature       Date:  2001-03-01       Impact factor: 49.962

6.  Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins.

Authors:  M Lachner; D O'Carroll; S Rea; K Mechtler; T Jenuwein
Journal:  Nature       Date:  2001-03-01       Impact factor: 49.962

7.  Set domain-containing protein, G9a, is a novel lysine-preferring mammalian histone methyltransferase with hyperactivity and specific selectivity to lysines 9 and 27 of histone H3.

Authors:  M Tachibana; K Sugimoto; T Fukushima; Y Shinkai
Journal:  J Biol Chem       Date:  2001-04-20       Impact factor: 5.157

8.  Comprehensive allelotype study of hepatocellular carcinoma: potential differences in pathways to hepatocellular carcinoma between hepatitis B virus-positive and -negative tumors.

Authors:  H Okabe; I Ikai; K Matsuo; S Satoh; H Momoi; T Kamikawa; N Katsura; R Nishitai; O Takeyama; M Fukumoto; Y Yamaoka
Journal:  Hepatology       Date:  2000-05       Impact factor: 17.425

9.  Lack of somatic mutation in the coding sequence of SIAH1 in tumors hemizygous for this candidate tumor suppressor gene.

Authors:  M Medhioub; C Vaury; R Hamelin; G Thomas
Journal:  Int J Cancer       Date:  2000-09-15       Impact factor: 7.396

10.  G9a histone methyltransferase plays a dominant role in euchromatic histone H3 lysine 9 methylation and is essential for early embryogenesis.

Authors:  Makoto Tachibana; Kenji Sugimoto; Masami Nozaki; Jun Ueda; Tsutomu Ohta; Misao Ohki; Mikiko Fukuda; Naoki Takeda; Hiroyuki Niida; Hiroyuki Kato; Yoichi Shinkai
Journal:  Genes Dev       Date:  2002-07-15       Impact factor: 11.361

View more
  61 in total

Review 1.  Functional Crosstalk Between Lysine Methyltransferases on Histone Substrates: The Case of G9A/GLP and Polycomb Repressive Complex 2.

Authors:  Chiara Mozzetta; Julien Pontis; Slimane Ait-Si-Ali
Journal:  Antioxid Redox Signal       Date:  2014-12-19       Impact factor: 8.401

2.  The interconnectedness of cancer cell signaling.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2011-12       Impact factor: 5.715

3.  Status of epigenetic chromatin modification enzymes and esophageal squamous cell carcinoma risk in northeast Indian population.

Authors:  Virendra Singh; Laishram C Singh; Avninder P Singh; Jagannath Sharma; Bibhuti B Borthakur; Arundhati Debnath; Avdhesh K Rai; Rup K Phukan; Jagadish Mahanta; Amal C Kataki; Sujala Kapur; Sunita Saxena
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

4.  Cancer subclonal genetic architecture as a key to personalized medicine.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2013-12       Impact factor: 5.715

Review 5.  G9a, a multipotent regulator of gene expression.

Authors:  Shilpa Rani Shankar; Avinash G Bahirvani; Vinay Kumar Rao; Narendra Bharathy; Jin Rong Ow; Reshma Taneja
Journal:  Epigenetics       Date:  2012-12-20       Impact factor: 4.528

6.  The histone H3 methyltransferase G9A epigenetically activates the serine-glycine synthesis pathway to sustain cancer cell survival and proliferation.

Authors:  Jane Ding; Tai Li; Xiangwei Wang; Erhu Zhao; Jeong-Hyeon Choi; Liqun Yang; Yunhong Zha; Zheng Dong; Shuang Huang; John M Asara; Hongjuan Cui; Han-Fei Ding
Journal:  Cell Metab       Date:  2013-12-03       Impact factor: 27.287

7.  RB1 methylation by SMYD2 enhances cell cycle progression through an increase of RB1 phosphorylation.

Authors:  Hyun-Soo Cho; Shinya Hayami; Gouji Toyokawa; Kazuhiro Maejima; Yuka Yamane; Takehiro Suzuki; Naoshi Dohmae; Masaharu Kogure; Daechun Kang; David E Neal; Bruce A J Ponder; Hiroki Yamaue; Yusuke Nakamura; Ryuji Hamamoto
Journal:  Neoplasia       Date:  2012-06       Impact factor: 5.715

8.  Expression of G9a in Auditory Cortex Is Downregulated in a Rat Model of Age-Related Hearing Loss.

Authors:  Qian Li; Yang-Hong Xiang; Xiao-Jun Liang; Yun Zhang; Peng-Peng Zhao; Min Wang; Xiao-Min Bao; Xian-Bai Zhu; An-Chun Deng
Journal:  J Mol Neurosci       Date:  2020-07-15       Impact factor: 3.444

Review 9.  Genomic and Epigenomic Alterations in Cancer.

Authors:  Balabhadrapatruni V S K Chakravarthi; Saroj Nepal; Sooryanarayana Varambally
Journal:  Am J Pathol       Date:  2016-07       Impact factor: 4.307

10.  Histone-lysine methyltransferase EHMT2 is involved in proliferation, apoptosis, cell invasion, and DNA methylation of human neuroblastoma cells.

Authors:  Ziyan Lu; Yufeng Tian; Helen R Salwen; Alexandre Chlenski; Lucy A Godley; J Usha Raj; Qiwei Yang
Journal:  Anticancer Drugs       Date:  2013-06       Impact factor: 2.248

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.